These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37445984)

  • 1. Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19.
    Matveev A; Pyankov O; Khlusevich Y; Tyazhelkova O; Emelyanova L; Timofeeva A; Shipovalov A; Chechushkov A; Zaitseva N; Kudrov G; Yusubalieva G; Yussubaliyeva S; Zhukova O; Baklaushev V; Sedykh S; Lifshits G; Tikunov A; Tikunova N
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel B-Cell Epitopes of Non-Neutralizing Antibodies in the Receptor-Binding Domain of the SARS-CoV-2 S-Protein with Different Effects on the Severity of COVID-19.
    Matveev AL; Pyankov OV; Khlusevich YA; Tyazhelkova OV; Emelyanova LA; Timofeeva AM; Shipovalov AV; Chechushkov AV; Zaitseva NS; Kudrov GA; Yusubalieva GM; Yussubaliyeva SM; Zhukova OA; Tikunov AY; Baklaushev VP; Sedykh SE; Lifshits GI; Tikunova NV
    Biochemistry (Mosc); 2023 Sep; 88(9):1205-1214. PubMed ID: 37770389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.
    Ricke DO
    Front Immunol; 2021; 12():640093. PubMed ID: 33717193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection.
    Okuya K; Hattori T; Saito T; Takadate Y; Sasaki M; Furuyama W; Marzi A; Ohiro Y; Konno S; Hattori T; Takada A
    Microbiol Spectr; 2022 Apr; 10(2):e0155321. PubMed ID: 35319248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
    Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
    Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
    Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
    Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
    Wang YT; Allen RD; Kim K; Shafee N; Gonzalez AJ; Nguyen MN; Valentine KM; Cao X; Lu L; Pai CI; Johnson S; Kerwin L; Zhou H; Zhang Y; Shresta S
    Antiviral Res; 2021 Nov; 195():105185. PubMed ID: 34634289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
    Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
    Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
    Lai R; Zhou T; Xiang X; Lu J; Xin H; Xie Q
    Front Med; 2021 Aug; 15(4):644-648. PubMed ID: 33909259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody levels and protection from COVID-19.
    Stadler E; Burgess MT; Schlub TE; Khan SR; Chai KL; McQuilten ZK; Wood EM; Polizzotto MN; Kent SJ; Cromer D; Davenport MP; Khoury DS
    Nat Commun; 2023 Jul; 14(1):4545. PubMed ID: 37507368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo.
    Wang Q; Peng L; Nie Y; Shu Y; Zhang H; Song Z; Li Y; Hu H; Li L; Wang X; Liu J; Li J; Shi Z; Deng F; Guo Y; Zhou Y; Yan B; Hu Z; Wang M
    Virol Sin; 2023 Apr; 38(2):257-267. PubMed ID: 36596381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
    Zhang C; Wang Y; Zhu Y; Liu C; Gu C; Xu S; Wang Y; Zhou Y; Wang Y; Han W; Hong X; Yang Y; Zhang X; Wang T; Xu C; Hong Q; Wang S; Zhao Q; Qiao W; Zang J; Kong L; Wang F; Wang H; Qu D; Lavillette D; Tang H; Deng Q; Xie Y; Cong Y; Huang Z
    Nat Commun; 2021 Jan; 12(1):264. PubMed ID: 33431876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Evidence for Human Monocyte-Derived Macrophage Infection and Antibody-Mediated Enhancement of SARS-CoV-2 Infection.
    García-Nicolás O; V'kovski P; Zettl F; Zimmer G; Thiel V; Summerfield A
    Front Cell Infect Microbiol; 2021; 11():644574. PubMed ID: 33912475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mAb broadly neutralizes SARS-CoV-2 VOCs in vitro and in vivo, including the Omicron variants.
    Kan Q; Lin X; Li T; Ke X; Jian X; Hou L; Zhang W; Wan Z; Xie Q; Shao H; Ye L; Ye J; Qin A; Zou Z; Chen Q
    J Med Virol; 2023 Mar; 95(3):e28657. PubMed ID: 36912367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.